Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
NCT00142051Phase 2Terminated
- Sponsor
- Boston Children's Hospital
- Start
- Apr 2005
- Primary completion
- Aug 2013
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Inhaled Nitric Oxide with Placebo (2 arms). Primary endpoint: Difference in change in mean pain score (visual analog scale) at 16 hours. Started Apr 2005; status: terminated.
02
Drugs
nitric oxide
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00142051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142051.